Fortive Corporation (NYSE: FTV) — Better Growth, Cheaper Price, Same Accounting Caveats

Independent fundamental research. Report date: 2026-09-03. Market data are through the September 2, 2026 close. All figures are continuing operations (“New Fortive”/RemainCo) unless noted; Precision Technologies was spun off as Ralliant Corporation on June 28, 2025.

⚡ Claude’s Take

This block is the author’s own independent, subjective opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The detailed analysis that follows takes no position and carries no price target; that discipline is intact everywhere except inside this fenced block.

Verdict: BUY / accumulate in a $53–$58 entry zone (17.7–19.3x the midpoint of FY2026 adjusted-EPS guidance); do not chase a return to the mid-$60s without another normalized 4%+ core-growth quarter. Conviction: medium. Tag: “The growth test improved; the price got cheaper.”

The July thesis was a good business at a price that assumed unproven growth. Both sides improved. Q2 core revenue rose 6.7%, including 4.3% volume, and management raised FY core growth to approximately 4% and adjusted EPS to $2.95–$3.05. Yet the shares fell 7.1% on July 29 and closed September 2 at $56.60, 9.7% below the July review price. The current quote is 18.9x the $3.00 guidance midpoint, 16.4x standardized reported / 15.5x company-adjusted EBITDA, and a 6.1% trailing equity FCF yield. Fluke, Sterrad and Landauer supply real brand, installed-base and compliance captivity; trailing FCF reached $1.044 billion. That quality now comes at a workable price.

The inflection is not settled. H1 core growth of 6.1% included Q1 calendar help, while the annual outlook implies roughly 2% in H2 and a four-selling-day Q4 headwind. Only 80 basis points of Q2’s 240-basis-point GAAP operating-margin gain came from pricing, volume, productivity and streamlining; AHS adjusted margin fell 80 basis points. Goodwill/intangibles remain 81% of assets, H1 tax was 14.4%, and roughly 11% share retirement over four quarters was partly debt-funded. Still, a 6.1% FCF yield plus 3%–4% aggregate FCF growth can support high-single-digit to low-double-digit returns without re-rating. This is a quality-compounder-at-a-reset-price call, not momentum: the stock is below its 21-, 50- and 200-day exponential averages, loads negatively on Momentum and Growth, and suffered a largely issuer-specific Q2 reset.

What would invalidate this call: two consecutive normalized quarters below 2% core growth; AHS margin failing to recover while IOS decelerates; net leverage moving above 3.0x to sustain repurchases; or a guided tax rate normalization that removes more than a tenth of adjusted EPS. What would increase conviction: normalized core growth at or above 4% through the selling-day noise, recurring revenue again outgrowing the company, underlying operating margin expanding at least 50 basis points without restructuring/tariff-refund help, and stable leverage despite continued net share retirement.

📈 Stock Price Action — Five-Year Event Map

Factual five-year price history for context. Price moves are Facts; attributed drivers are Interpretation. No price target, no support/resistance, no chart-pattern reading. The critical caveat below: the AZI price series is spin-adjusted, so pre-June-2025 prices are marked down ~25% for the Ralliant distribution — a mechanical adjustment, not a repricing.

Over the trailing roughly 60 months Fortive has effectively been two securities, and the tape must be read through that lens. The adjusted price series moved from roughly $53 in mid-2021 to a $64 adjusted peak in February 2024, a $46.77 post-spin low in August 2025, a $64.09 post-spin high on July 28, 2026, and $56.60 on September 2. Pre-spin prices are mechanically adjusted for the Ralliant distribution; the June 2025 step-down was not a fundamental loss. The newest event is more informative: shares fell from $64.09 before Q2 results to $59.54 on July 29 even though Fortive beat and raised, then drifted to $56.60 below both its 50-day and 200-day exponential averages. Price facts come from the AZI daily-price series; causal attributions below are interpretation.

Cycle narrative. Events 1–4 belong to the pre-spin combined entity. Event 6 must not be mistaken for fundamental weakness: holders received Ralliant stock. Events 7–9 are the useful standalone record. The initial orphan selloff reversed as Fortive beat expectations and retired shares, but Q2 2026 shows that expectations had outrun the reported numbers. The approximately 12% pullback from the pre-earnings high occurred while the fundamental outlook improved, resetting the valuation reference point.

Changes Since the July 4, 2026 Review

The prior memo concluded that quality was fully reflected at $62.65 and said the view would improve with normalized 4%+ core growth or a materially lower valuation. Neither threshold was met perfectly, but both moved far enough to change the conclusion.

The strongest prior bear claim—that Fortive was a 2% grower requiring buybacks to manufacture the entire per-share story—has weakened. The strongest prior bull claim—that the re-rating already discounted a clean organic inflection—was validated by the post-Q2 selloff. The remaining debate is whether H1 represents a new 4% normalized trajectory or merely calendar, comparison and product-cycle help.

1. Executive Summary

Fortive is the highest-quality remainder of a company repeatedly simplified since its 2016 Danaher separation. After the 2020 Vontier and 2025 Ralliant spins, it is a two-segment industrial-and-healthcare technology company with trailing revenue of $4.316 billion. Intelligent Operating Solutions (IOS) contributes roughly 69% through Fluke professional test, facility and asset-lifecycle software, and gas detection. Advanced Healthcare Solutions (AHS) supplies Sterrad sterilization, instrument tracking, radiation dosimetry and clinical-workflow software. The portfolio remains capital-light and cash-rich: trailing operating cash flow and free cash flow were $1.158 billion and $1.044 billion.

Business quality is above average but not uniform. Fluke’s trusted brand and distribution create customer captivity; Sterrad combines regulated workflows with proprietary consumable pull-through; Landauer sits inside mandatory compliance; and software switching costs are useful but contestable. The Fortive Business System is a repeatable operating capability, not a customer-facing moat. The balance sheet preserves the acquisition prices paid for these franchises: at Q2, goodwill was $7.340 billion and acquired intangibles $2.022 billion, together about 81% of assets. This creates the central return-on-capital split—excellent economics on tangible operating capital, mediocre consolidated returns on all acquisition capital.

Growth is the major update. FY2025 core growth was only 1.7%, entirely price-led. Q2 2026 core growth accelerated to 6.7%, with 4.3% volume; IOS core rose 7.4% and AHS 5.3%. Management lifted the annual expectation to approximately 4%. Nevertheless, H1’s 6.1% mathematically implies a much slower H2, Q1 benefited from extra selling days, and Q4 loses four selling days. Evidence now supports a 3%–4% normalized range, but not a permanent 5%–6% trajectory.

Earnings quality is good in cash terms and complicated in accounting terms. Trailing FCF exceeds $1 billion and capex remains modest. Adjusted EPS excludes acquired-intangible amortization but includes stock compensation, a comparatively honest choice. First-half stock compensation was $45.2 million. The H1 effective tax rate remained low at 14.4%. Only one-third of Q2’s GAAP operating-margin improvement came from recurring operational levers. Investors should use both GAAP and adjusted views: GAAP captures acquisition cost; adjusted results better approximate current cash operations, but neither alone is sufficient.

Capital allocation has shifted from spin execution to repurchases and small bolt-ons. Fortive bought approximately $700 million of shares in H1 2026, including 3.36 million Q2 shares at an average $59.54. Over four quarters it spent about $2 billion and reduced shares by roughly 11%. This was accretive near the current valuation, but not self-funding indefinitely: net debt rose to about $3.14 billion and gross debt to $3.51 billion. The €51 million UV Smart majority investment is strategically adjacent to ASP, yet most of the recorded purchase price became goodwill and intangibles—an early reminder that deal discipline, not deal logic, determines value creation.

At the September 2 close of $56.60, 302.0 million reported shares imply a $17.09 billion equity value. Rebuilt enterprise value is about $20.24 billion, or 4.69x trailing sales and 16.4x trailing EBITDA. The stock is 18.9x the midpoint of FY2026 adjusted-EPS guidance and carries a 6.1% trailing equity FCF yield. Own-history valuation percentiles remain elevated—AZI reports a composite near the 84th percentile—but pre/post-spin comparability is imperfect. Against current quality-industrial peers, Fortive is no longer an obvious premium outlier.

The thesis therefore changed from quality at a full price to quality at a workable price with a partially validated growth inflection. The load-bearing questions are now narrower: can normalized core growth hold at least 3%–4%; can underlying margin expand after stripping amortization, restructuring and refunds; and can repurchases continue without net leverage exceeding roughly 3x? A positive answer to the first two makes the present valuation reasonable even if buybacks normalize. Failure on both would reveal that H1 was a temporary bounce and leave too much of EPS growth dependent on the balance sheet.

2. Business Overview

Fortive’s FY2025 Form 10-K describes the third leg of a serial de-conglomeration that began when the company was spun out of Danaher in July 2016. On June 28, 2025, Fortive separated Precision Technologies into Ralliant Corporation in a tax-free spin. RemainCo is a two-segment industrial-and-healthcare technology company headquartered in Everett, Washington, with roughly 10,000 employees across approximately 50 countries and FY2025 continuing revenue of $4,159.1 million (2024: $4,080.9 million; 2023: $3,913.9 million).

Segment 1 — Intelligent Operating Solutions (IOS): $2,856.3M, 68.7% of revenue (Fact; 10-K Note 16). This is the larger and higher-quality half, materially bigger than the “~60%” framing that circulated pre-spin — post-spin Fortive is nearly 70% IOS. IOS sells professional instruments, facility/asset-lifecycle software, and connected-worker safety solutions under six brands: FLUKE (handheld electrical test & measurement — the crown jewel, ~40% of the whole company), ACCRUENT, GORDIAN, SERVICECHANNEL (facility and asset-lifecycle / IWMS software), INDUSTRIAL SCIENTIFIC (portable gas detection / connected-worker safety), and INTELEX (EHSQ compliance software). End users are electricians, network engineers, EHS professionals, facility managers, and first responders. IOS carries a 25.8% GAAP segment operating margin and 65.9% gross margin — genuinely attractive economics.

Segment 2 — Advanced Healthcare Solutions (AHS): $1,302.8M, 31.3% of revenue (Fact; 10-K Note 16). AHS supplies hospital-workflow solutions under ADVANCED STERILIZATION PRODUCTS (“ASP” / STERRAD low-temperature sterilization), CENSIS (CensiTrac surgical-instrument tracking), FLUKE BIOMEDICAL, LANDAUER (radiation dosimetry service), PROVATION (clinical/GI productivity software), RAYSAFE and INVETECH. AHS reports a 10.6% GAAP segment operating margin — but that number is misleading. Amortization of acquired intangibles runs 13.8% of AHS sales versus 6.6% at IOS; add it back and AHS operates at a mid-20s cash margin. AHS gross margin is 58.1%. The optically thin GAAP margin is an artifact of how expensively these businesses were bought, not of the businesses’ underlying economics.

Revenue model and mix. Fortive combines durable instruments and capital equipment, installed-base consumables, recurring calibration/compliance services, and subscription software. Management’s June 2025 Investor Day described RemainCo as approximately 50% recurring, but the Q2 filing does not reconcile that definition. Filed service revenue was $220.0 million, or 20.1% of Q2 sales; products and software are combined in the other category. Management evidently includes software, consumables, rentals and subscriptions in its broader number. Remaining performance obligations were $824.8 million, down 1.9% from year-end, while contract liabilities rose 2.6% to $476.7 million. This supports the existence of a recurring installed base, but does not validate the 50% denominator or an acceleration. A counterintuitive filing detail is that the formal service category generated about a 48% gross margin versus about 67% for product/software; more filed service mix is therefore not automatically margin-accretive.

End markets and geography (Fact; 10-K disaggregation, FY2025): Healthcare $1,280.5M (essentially all of AHS), Industrial & Manufacturing $1,198.7M, Energy & Infrastructure $687.6M, Government $350.6M, Retail $315.7M (facility software for multi-site operators), Other $326.0M. The company is US-centric — North America is 60% of sales ($2,491.1M); the balance is APAC $730.1M (18%), EMEA $725.8M, and LatAm $212.1M.

A capital-light business dressed in a heavy balance sheet. FY2025 capital expenditure was only $105.1 million, or 2.5% of sales, and trailing capex remains 2.6%. Yet recalculated acquisition-inclusive GAAP ROIC is only about 6.7%, because the balance sheet carries $9.36 billion of goodwill and intangibles. That return measures what Fortive paid for its businesses, not only the incremental economics of running them; the 30.2% adjusted EBITDA margin and modest capex imply much higher tangible operating returns.

Verdict. Post-spin Fortive is a capital-light, brand-and-software-anchored industrial-healthcare compounder, ~69% weighted to the higher-quality IOS segment. The spin’s stated purpose — a higher-margin, higher-recurring “quality” RemainCo — is directionally credible on capital-intensity and gross margin, but two cautions stand: (1) the marquee “~50% recurring” figure is a management definition the 10-K does not substantiate (filed services = 20%), and (2) AHS, a third of revenue, is the structurally slower-growing and optically weaker half. This is a good business, but the label needs auditing, not adopting.

3. Industry Dynamics

Fortive competes across five distinct market structures, and they are not equally attractive. I assess each, then render an aggregate verdict and locate the portfolio in Marathon capital-cycle terms.

Cycle and market-size context. Fortive does not disclose comparable product-level total-addressable markets, and public industry estimates define categories inconsistently, so precise TAM figures would create false confidence. The more reliable evidence is demand cadence across Fortive and direct peers. Professional instruments remain short-cycle and exposed to industrial maintenance budgets; healthcare consumables/service are steadier than sterilizer capital; dosimetry is mature and regulation-supported; vertical software offers secular digitization but heavier feature competition. With 60% of FY2025 revenue in North America and the rest distributed across APAC, EMEA and Latin America, growth is global but not insulated from regional industrial, hospital-capital and currency cycles. Volume contracted in 2025 and recovered in H1 2026, placing current earnings closer to a cyclical recovery than an obvious peak; margins, by contrast, are near a post-spin high.

1. Professional test and measurement (Fluke). This is Fortive’s best industry, but it spans many subcategories rather than one auditable market-share pool. Competition includes Keysight, Tektronix, Klein Tools, HIOKI, VIAVI and lower-cost Asian brands. Safety-criticality, ruggedness, technician habit, calibration history and distribution favor trusted incumbents. Technology alone is not a durable barrier: VIAVI launched a native 12/16/24-fiber certification product close to Fluke’s CertiFiber Max launch. Barriers are demand-side trust, workflow and service scale, not exclusive hardware. Structurally good and innovation-intensive.

2. Facility / asset-lifecycle and EHSQ software (Accruent, Gordian, ServiceChannel, Intelex). The weakest industry structurally. IBM Maximo, Nuvolo, Siemens/Brightly, eMaint, Fiix, MaintainX, UpKeep and many specialists contest adjacent categories. Low physical-capital barriers and rapid generative-AI feature supply keep entry active. Fortive’s edge is account-level workflow, proprietary data at Gordian and ServiceChannel’s provider/work-order dataset, not category-wide dominance. Structurally average and contestable.

3. Portable gas detection and connected-worker safety (Industrial Scientific). OSHA confined-space rules mandate calibrated hazard testing but are vendor-neutral. Honeywell, MSA Safety and Dräger are serious scaled competitors. Regulation creates a durable demand floor and hardware-as-a-service can embed fleet records, calibration and training; hardware pricing is still checked by alternatives. Structurally good, competitively contested.

4. Medical low-temperature sterilization and instrument tracking (ASP, Censis). This is an attractive regulated niche with a limited set of credible incumbents, including STERIS and Getinge. FDA reprocessing guidance requires scientifically validated device-specific instructions and trained workflows, which raises entry and switching costs. It is not an exclusive legal moat: FDA records show multiple cleared systems and accessories compatible with competing platforms. The installed base, staff training, workflow validation, consumables and service matter more than clearance alone. Recent peer evidence is constructive but recurring-led: STERIS reported 10% service and 9% consumables growth versus 1% healthcare capital-equipment growth. Structurally good, with capital bids more competitive than consumables pull-through.

5. Radiation dosimetry (Landauer). Occupational monitoring creates recurring demand, and NRC rules require covered licensees to use an NVLAP-accredited processor. Accreditation is open to qualified processors, so it is a hurdle rather than a franchise grant. Badge administration, longitudinal dose records and compliance integrations create modest customer captivity; Mirion is a scaled alternative. Structurally stable and low-growth.

Aggregate verdict and capital-cycle read. Structurally good on balance, with one soft spot. Brand, validated workflows, accreditation, service networks and installed software/consumables constrain supply more than manufacturing capacity. No portfolio category shows commodity-style greenfield overbuilding, but incumbents are actively reinvesting: STERIS is adding chemistry capacity over several years, MSA is consolidating safety assets, test vendors are matching data-center features, and software feature supply is expanding rapidly. Under the Marathon framework, returns are best protected where validation and installed workflows slow entry (ASP/Landauer) and least protected where code/features can enter quickly. The portfolio’s fastest narrative areas—AI software and data-center testing—also face the quickest competitive response.

4. Competitive Position

Fortive’s moat is brand-by-brand, not corporate-wide, and it ranges from genuinely durable to merely adequate. Assessing each through the Greenwald taxonomy (supply/cost advantage; demand/captivity; economies-of-scale-plus-captivity):

Fluke—the strongest moat: brand, workflow and distribution (demand captivity). Management says Fluke supplies more than 40% of Fortive revenue, but category share is not disclosed. The mechanism is trust and habit in safety-critical, high-consequence work: technicians learn interfaces and safety practices, fleets build calibration/service histories, and broad distribution lowers search and downtime. Fortive also owns value-positioned Amprobe and Extech. Standalone meters have limited hard switching costs and competitors can match features; fleets and service relationships are stickier. IOS’s economics—34.9% Q2 adjusted EBITDA margin—are consistent with a valuable franchise but do not prove product share. Verdict: durable narrow-to-moderate moat.

ASP / Sterrad — the second-strongest: installed-base captivity plus regulatory switching costs (economies-of-scale-plus-captivity). Sterrad is a razor/razor-blade model: hospitals install a sterilizer, validate device workflows, train staff and purchase cycle consumables. Those operational and infection-control costs discourage casual switching. FDA clearance raises the cost and time of entry for all vendors, but multiple STERIS, Sterrad and other systems are cleared; it does not grant exclusivity. The moat is strongest inside an installed account and narrower when a hospital reaches a replacement decision. Fortive does not disclose installed-base share, placement wins or consumables attachment, so precise market-share claims are not supportable from public primary evidence. Verdict: durable moderate moat in the installed base, with credible competition for new placements.

Landauer — regulatory-mandated recurring service (demand captivity + switching costs). Occupational dosimetry is required for covered workers; Landauer supplies badges, processing and reports. Once historical dose records and compliance integrations are established, changing processors adds friction to a low-cost, mission-critical workflow. NVLAP accreditation is achievable by qualified rivals, and Mirion is scaled. Fortive does not disclose retention, badge count or share. Verdict: durable narrow moat, but low-growth and not exclusive.

Software (Accruent, Gordian, ServiceChannel, Intelex, Censis, Provation) — real but shallower switching costs in a contestable market. Data, workflows, integrations and training create standard SaaS friction, but competitors include IBM Maximo, Nuvolo, Siemens/Brightly, eMaint, Fiix and MaintainX. Gordian’s RSMeans construction-cost data are the strongest proprietary asset. ServiceChannel says its marketplace spans more than 70,000 providers and 220 million work orders, which can lower search costs, though providers can multi-home and transact directly. Flash AI has a visible $5,000-per-user annual price, proving productization rather than portfolio financial impact. Fortive discloses no ARR, organic ARR, gross retention, net revenue retention or AI contribution. Verdict: mixed narrow moats; not yet supported at Roper-like confidence.

Pressure-testing FBS as a moat. The Danaher-derived Fortive Business System is a real operating capability: recurring productivity and the four-quarter adjusted-margin record demonstrate execution. But it is not a customer-facing moat. It does not by itself raise switching costs, and other industrial operators use lean systems. Under the Greenwald test, FBS is management capability rather than an entry barrier. It can widen operating margins and improve acquired businesses without protecting demand from competitors.

Low-cost competition and unrecorded assets. Foreign low-cost labor is not the principal threat because Fortive sells trusted measurement, validated healthcare workflows, compliance records and software rather than labor hours. Lower-cost Asian meters can pressure entry tiers, and software code can be produced cheaply; Fluke’s trust/distribution and installed workflow are the defenses. The balance sheet does not separately recognize most internally developed brand equity, customer workflow knowledge, calibration history, RSMeans data or ServiceChannel marketplace data. Those assets help explain high gross margins and negative tangible invested capital. The counterweight is that acquisition goodwill already capitalizes the price Fortive paid for many customer relationships, so investors should not add an unrecorded-brand premium without also retaining the acquisition-inclusive ROIC penalty.

Verdict. Durable advantage, concentrated and uneven. Fluke and installed Sterrad accounts carry the strongest demand captivity; Landauer and gas HaaS have narrower regulatory/workflow advantages; Gordian and ServiceChannel are the more defensible software assets. FBS is operational, not competitive. Approximately 6.7% acquisition-inclusive GAAP ROIC understates tangible operating economics but accurately warns that prior purchase prices absorbed much of the value. Durability is anchored in specific brands and installed workflows, not spread uniformly across Fortive.

5. Growth History and Forward Opportunities

The 2026 inflection is real, even if its durability is not. Q2 revenue reached $1,096.8 million, up 7.9% reported and 6.7% core. Price contributed 2.4% and volume 4.3%. IOS core growth was 7.4%, comprising 2.7% price and 4.8% volume; AHS core growth was 5.3%, comprising 1.9% price and 3.4% volume. H1 core growth was 6.1%, with 3.8% volume. This is a material contradiction of the 2025 picture in which price supplied all organic growth and volume declined. Q2 had no selling-day benefit, making it the cleanest post-spin growth observation to date.

The restraint is arithmetic and comparison quality. Q1 had four extra selling days worth approximately 150 basis points of core growth, Q2 compared against a softer 2025 period, and Q4 2026 will have four fewer selling days worth an estimated 150 basis points or $15–$20 million. Management’s approximately 4% full-year core outlook, against 6.1% in H1, implies roughly 2% in H2. Management expects Q3 to be near 4%, which leaves a calendar-depressed Q4 near flat. The normalized trajectory has plausibly improved from 2%–3% to 3%–4%; it has not yet become 6%.

Historical growth — modest organic, historically M&A-augmented. On a continuing-operations recast basis, revenue moved $3,913.9 million (2023) to $4,080.9 million (2024) to $4,159.1 million (2025), roughly 4.3% and 1.9% reported growth. FY2025 core growth was 1.7%, consisting of 2.2% price and negative 0.6% volume. The H1 2026 result breaks that pattern. It does not alter the structural ceiling: Fortive’s mature niches, recurring mix and pricing can support mid-single-digit organic growth in a good period, not double-digit organic compounding.

Segment composition and trajectory. Growth decelerated across both segments in 2025: IOS core slowed from 3.5% in 2024 to 2.1% in 2025; AHS moved from 6.1% to 0.8% as sterilization capital and biomedical test softened. H1 2026 was broad rather than one-product driven. Q2 professional instrumentation, facilities/asset software and gas detection led IOS; sterilization led AHS. Management said Fluke orders modestly exceeded revenue and its recurring calibration/software/service stream has grown double digits for several quarters, but provided no Fluke revenue, mix or retention. The broad positive volume is stronger evidence than the unquantified product anecdotes.

Recurring-revenue mix—the quality upgrade claim. Management says recurring revenue has grown faster than total revenue and software ahead of the company. If sustained, subscriptions, calibration, consumables and services should improve durability. Public filings do not reconcile the roughly 50% recurring definition, and RPO declined modestly from year-end, so this remains a plausible management hypothesis rather than a proven mix shift.

Forward opportunities, weighed honestly. (1) Data-center operations for Fluke. CertiFiber Max demand exceeded plan and may pull through power-quality, battery, imaging and calibration products. Management explicitly cautions that Fluke is not a data-center company, and VIAVI’s parallel product shows feature competition. Treat this as a credible accelerator, not a quantified thesis pillar. (2) Software and AI. ServiceChannel, eMaint and Gordian have launched products and multiple monetization models; Gordian Flash AI has visible pricing. No AI revenue, attachment, retention or margin contribution is disclosed. Productization is proven; financial acceleration is not. (3) Healthcare recurrence. ASP consumables and services were strong across regions, and a higher-capacity Sterrad clearance expands robotic-instrument use cases. Direct peers show recurring service/consumables growing much faster than capital, arguing for steady installed-base growth rather than a hospital-capex boom. (4) Gas detection HaaS. Strong regional demand could represent a better recurring model, but Fortive discloses no fleet count, ARR or renewal rate. (5) FBS and small bolt-ons. Operating discipline and UV Smart can add modestly, subject to the price paid.

Verdict — upgraded from structurally low to improving, not yet proven. H1 volume growth falsifies the claim that Fortive remains stuck at a price-only 2% rate. A reasonable normalized assumption is now 3%–4% core growth, with 4% the clean Q3 hurdle. The composition remains imperfectly disclosed, and none of data centers, AI, HaaS or healthcare placements is quantified. Sustainable positive volume plus recurring pull-through can support genuine per-share compounding; one strong clean quarter cannot establish it.

6. Financial Quality

Current run rate. Reconstructing the four standalone quarters through Q2 from Fortive’s filed earnings exhibits produces $4,315.8 million of revenue, $786.7 million of GAAP operating profit, approximately $1,304.1 million of company-defined adjusted EBITDA, $1,158.0 million of continuing-operations cash from operations and $1,044.3 million of free cash flow. GAAP operating margin was 18.2%, adjusted EBITDA margin 30.2% and FCF margin 24.2%. FCF rose about 11% year over year. Filing-defined FCF is operating cash flow less $113.7 million of capex, not operating cash flow relabeled as FCF.

Quarterly progression supports real scale economics. Revenue growth advanced from 2.3% in Q3 2025 to 4.6%, 7.7% and 7.9%; core growth moved from 1.9% to 3.3%, 5.3% and 6.7%. Company-defined adjusted EBITDA margin expanded year over year in each quarter—by approximately 220, 90, 140 and 110 basis points—and trailing margin rose about 139 basis points. The prior margin falsifier, two quarters of flat or declining adjusted margin, was not triggered. Yet Q2 makes the distinction between adjusted and GAAP bridges essential. Fortive excluded the $4.5 million tariff refund from adjusted EBITDA, so adjusted expansion is cleaner than the 240-basis-point GAAP gain; AHS’s adjusted margin still contracted 80 basis points.

Revenue and margin structure — GAAP vs. adjusted, and the amortization wedge. Gross margin is a healthy 63.5% (down 70 bps YoY on tariff and mix), evidencing genuine pricing power and an asset-light, instrument-and-software mix. But GAAP operating margin is only 17.3% ($720.2M), while management’s adjusted operating margin is ~26% and adjusted EBITDA margin ~29.6% ($1,233M; note the aggregator’s unadjusted EBITDA is $1,157.8M / 27.8%). The ~9-point GAAP-to-adjusted gap is almost entirely amortization of acquired intangibles — $367.5M, or 8.8% of sales — the accounting unwind of a decade of acquisitions. This is the defining feature of a Danaher-heritage serial acquirer: GAAP earnings are structurally depressed by the amortization of the very deals that built the company. The add-back is legitimate for cash purposes (amortization is non-cash), but it is a permanent reminder that GAAP profitability understates cash economics while reported returns on capital overstate the quality of the price paid.

The GAAP-to-adjusted EPS bridge is clean and worth stating precisely (Q4’25 release): GAAP continuing-ops EPS $1.59 + acquisition-intangible amortization $1.10 + acquisition/divestiture/separation items $0.13 + discrete restructuring $0.10 − tax effect $0.20 = adjusted diluted EPS of $2.71 (FY2024: $2.41; +12.4%). Fully 98% of the $1.12 wedge was amortization. Stock compensation was not added back. Current FY2026 guidance is $2.95–$3.05 of adjusted EPS, approximately $4.35 billion of revenue and roughly 4% core growth.

A quality-of-earnings flag on tax. The effective tax rate was 11.5% (2025), 4.7% (2024), 5.7% (2023) — extraordinarily low versus the 21% U.S. statutory rate, driven by foreign-earnings mix and credits. This flatters both GAAP and adjusted EPS. Were the rate to normalize toward the low-20s — a live risk given the OBBBA and OECD Pillar Two “Side-by-Side” regime the company flags — adjusted EPS would fall on the order of 12–15%, all else equal (Interpretation). The sustainability of a sub-12% rate is a genuine open question and one of the larger swing factors in the earnings algorithm.

Free cash flow quality and conversion — the best part of the story. Continuing-operations operating cash flow was $1,035.7M; capex just $105.1M (2.5% of sales); free cash flow $930.6M (FY2024: $942.4M — notably down YoY despite higher revenue, on separation cash costs and higher capex). FCF converts at 103% of adjusted net earnings and ~175% of GAAP continuing net income. On the quality-of-earnings test — is net income diverging from cash? — the answer is favorable: cash exceeds GAAP earnings (OCF $1,035.7M vs. GAAP continuing net income $532.7M), the gap explained by $437.6M D&A and $116.8M non-cash SBC. There is no working-capital-fueled earnings mirage; if anything, GAAP understates the cash. (Note: total-company OCF of $1,083.2M in the statement includes a half-year of Ralliant discontinued operations and should be discarded for run-rate.)

SBC and dilution. Trailing stock compensation was approximately $116 million, 2.7% of revenue, 11.1% of FCF and 19.3% of GAAP continuing net income. Fortive does not add SBC back to adjusted EPS. H1 2026 SBC was approximately flat year over year even as adjusted EPS accelerated. Buybacks overwhelmed issuance: Q2 diluted weighted shares fell 10.0% to 307.6 million, and the July 24 cover count was 302.0 million. Per-share improvement is therefore genuine, but a large portion is capital-allocation rather than operating performance.

The ROIC question—the honest answer. On roughly $9.24 billion of average acquisition-inclusive invested capital, trailing GAAP operating profit taxed at a normalized 21% produces NOPAT near $622 million and ROIC near 6.7%. Adding after-tax acquisition amortization produces a cash-NOPAT return around 9.9%. Both improved from the July estimates of roughly 6.1% and 9.2%, respectively, but the first remains below and the second merely around a reasonable cost of capital. Goodwill plus intangibles were $9.36 billion, 80.6% of assets. Tangible invested capital is negative, consistent with excellent asset-light operations; acquisition-inclusive returns remain modest, consistent with Fortive having paid away much of the franchise value. The operations improved. The historical purchase prices did not disappear.

Balance sheet. At Q2, cash was $374.2 million and carrying-value debt $3.509 billion, for net debt of approximately $3.135 billion and roughly 2.4x trailing adjusted EBITDA. The principal stack included $1.077 billion of commercial paper, $600 million of 4.75% 2031 notes, $500 million of 5.25% 2036 notes, $550 million of 4.30% 2046 notes and roughly $801 million of 3.70% euro notes. The $2.0 billion revolver was undrawn. The amended net-leverage covenant is 3.75x, rising temporarily to 4.25x after an acquisition larger than $250 million—not the 3.5x/4.0x threshold used in the July memo. The Q2 filing reports compliance. Net interest rose to $35.4 million in Q2 as cheaper obligations were refinanced. Deeply negative tangible equity remains an acquisition-accounting artifact, not immediate distress, but higher debt now funds part of the per-share algorithm.

Tax and working-capital sensitivity. The Q2 effective tax rate was 12.4% and H1 14.4%, compared with 20.1% and 18.0% in the prior periods. The half-year move is closer to a sustainable range than FY2024’s 4.7%, but trailing tax remains near 10% because Q4 2025 was unusually low. A 21% rate applied to pretax profit would materially reduce earnings. Both a 14%–16% and a 21% case belong in underwriting. Working capital is not masking a problem: cash conversion remains strong, contract liabilities rose, and capex is 2.6% of sales. Ordinary leases and contingencies do not appear large enough to change solvency; the economically important off-balance-sheet exposure is operational—warranties, product quality, cybersecurity, healthcare regulation and distributor/channel behavior—not a hidden financing vehicle.

Verdict—do economics improve with scale? Yes operationally; only modestly on all-in capital. Trailing revenue, adjusted EBITDA and FCF rose approximately 5.6%, 10.7% and 11.2%, demonstrating operating leverage and strong cash quality. But acquisition-inclusive ROIC remains around 6.7% GAAP or 9.9% after amortization, the tax rate is still unusually low, and AHS margin did not participate in Q2. The company is a high-quality operating cash machine attached to a balance sheet that records expensive historical M&A.

7. Capital Allocation

The 2026 cash test is the key update. The Q2 filing shows $700.3 million spent to repurchase 12.3 million shares in H1 at an average $57.13, versus $464.4 million of FCF, $18.4 million of dividends and $58.1 million of acquisitions. Total uses exceeded internally generated cash by approximately $312 million; net debt rose approximately $305 million, from $2.831 billion at year-end to $3.135 billion. Over the trailing four quarters, repurchases approached $1.97 billion against $1.04 billion of FCF. The share count fell and net leverage stayed near 2.4x because EBITDA grew, but the repurchases were plainly not self-funded. That is the crucial distinction between a stable leverage ratio and cash-funded compounding.

The model, and a telling three-year pause. Fortive is a Danaher-style operator built by acquiring instrument and vertical-software businesses and applying FBS. The $9.36 billion of goodwill and intangibles is the fossil record: Accruent (approximately $2.0 billion, 2018), Gordian ($775 million, 2018), Intelex/Censis/Prüftechnik (approximately $1.2 billion, 2019), Advanced Sterilization Products (approximately $2.7 billion, 2019), ServiceChannel (approximately $1.2 billion, 2021) and Provation ($1.425 billion, 2021). Cash paid for acquisitions then fell to $95.8 million in 2023, $3.6 million in 2024 and $25.7 million in 2025 while Fortive prepared the separation and emphasized repurchases. The engine restarted with UV Smart; terms initially went undisclosed and were later provided in the Q2 filing.

The Ralliant spin as a capital-allocation decision. The June 28, 2025 spin (one Ralliant share per three Fortive shares) was the marquee capital-allocation act, executed cleanly. Fortive extracted a $1.15B Ralliant Dividend plus cash proceeds and put it to disciplined use: $294M to redeem €252M of 3.7% 2026 notes, $421M to repay Euro/Yen term loans, and $483M to repurchase stock. Retained earnings fell $2.8B (to $5,428.5M), reflecting the carve-out distribution. The result is a higher-margin, more-recurring, more asset-light RemainCo with a delevered balance sheet — a defensible portfolio decision that concentrated Fortive on its better businesses.

The buyback—the real EPS engine. Fortive repurchased $1,610.1 million in 2025 at roughly $53.67 per share, then another $700.3 million in H1 2026. Q2 alone was 3.36 million shares at $59.54. Diluted Q2 shares fell 10% year over year, explaining a substantial portion of the 28.5% adjusted-EPS gain. This can create value when repurchases occur below intrinsic value, but recent scale cannot persist from free cash flow alone. Authorization is not the constraint: 17.7 million shares remained under the general program plus $66.7 million of special authority. The real constraints are opportunity cost, valuation and leverage. The formal covenant is 3.75x, but an investment-grade operator should not treat the legal maximum as a capital-allocation target.

Dividend and debt management. On August 20, Fortive raised the quarterly dividend 16.7% to $0.07, payable September 25. The annualized $0.28 is still only about a 0.5% yield and less than 10% of guided adjusted EPS; it signals confidence more than it returns meaningful cash. Debt management removed near-term maturities but raised the cost: $1.1 billion of new notes at 4.75% and 5.25% replaced cheaper funding.

UV Smart and the M&A restart. The Q2 10-Q reveals €51 million, approximately $58 million, of net cash for a majority interest, with Fortive obligated to acquire the remainder in early 2029 for up to €20 million. The business was immaterial to current revenue and profit. Fortive recorded approximately $52 million of non-tax-deductible goodwill and $20 million of intangibles, meaning about 90% of upfront cash reappeared as goodwill. Strategic fit with ASP is plausible; no disclosed revenue or EBITDA permits a purchase-multiple or accretion test. This is too small to move the thesis, but an appropriate first scorecard for the new team’s price discipline.

Incentives—the governance flag. The April 2026 proxy shows the 2025 company bonus factor at adjusted EPS 60%, FCF 20% and core revenue growth 20%; PSUs used 60% relative TSR and 40% three-year average core growth. The 2026 design raises PSUs to 60% of long-term incentives and makes the annual plan fully financial, subject to a limited personal modifier. No ROIC, ROE or RONA hurdle appears. That is a mismatch for a serial acquirer: adjusted EPS adds back acquisition amortization and rises mechanically with repurchases, while no pay metric tests returns on the capital consumed. Current directors and officers own less than 1% as a group. Ownership guidelines improved, but formal incentives still favor outcomes per share over acquisition-inclusive returns.

Insider behavior — one genuine signal. Against that low-ownership backdrop, the lone conviction data point is positive: new CFO Mark Okerstrom made an open-market purchase of 21,300 shares at $47.03 (~$1.0M) on August 1, 2025, just after the spin and near the post-spin low — real skin in the game from a fresh CFO. No other discretionary buying occurred; the rest of the Form 4 flow is routine grants, option exercises, and tax-withholding.

Verdict—has management allocated capital intelligently? Competent but not yet self-funding. The Ralliant spin and 2025 repurchases were defensible, and the dividend increase is harmless. The H1 2026 cash bridge is the warning: debt financed the gap between FCF and repurchases. Historical M&A has generated only cost-of-capital-like consolidated returns, while compensation still omits ROIC. Future value creation depends less on keeping adjusted EPS high than on choosing between shares and acquisitions at prices that raise per-share intrinsic value without leaning further on debt.

8. Changes and Headwinds — Last Two Years

The last twenty-four months reshaped the company more than any period since the Danaher spin. A material-event timeline and its thesis implications:

• Sep 4, 2024 — separation announced. Fortive announces the split into RemainCo (IOS + AHS) and Precision Technologies (later Ralliant). Strengthens the thesis’s clarity: management chose to concentrate on the higher-margin, more-recurring businesses.
• Jan 2025 / mid-2025 — leadership reset. Olumide Soroye (ex-CoreLogic; ran IOS from 2021 and AHS from Jan 2025) becomes CEO of RemainCo on separation, succeeding long-time CEO Jim Lico; Mark Okerstrom (ex-Expedia CEO) is CFO. A wholesale management reset — new, and unproven on capital-allocation price discipline (see Capital Allocation). Neutral-to-watchful.
• June 28, 2025 — Ralliant spin completes. $1.15B dividend to Fortive; proceeds used for debt paydown and buyback. Executes the portfolio decision cleanly; the ~25% price adjustment is mechanical, not fundamental (see the Stock Price Action section).
• H2 2025 — buyback acceleration. ~$1.3B repurchased, >10% of shares retired since the spin. The engine of reported EPS growth; sensible at ~$54 average, but leverage-bounded.
• Feb 4, 2026 — FY2025 results / FY2026 guide. Adjusted EPS $2.71 (beat), FY2026 guide $2.90–$3.00 on 2–3% core. Confirms the low-organic, buyback-levered algorithm.
• May 14, 2026 — $1.1B refinancing at 4.75%/5.25% (vs. retired 3.15%/3.7%). Raises current-year net-interest expectations to approximately $140 million; a modest structural headwind.
• June 24, 2026 — ASP/UV Smart bolt-on. Fortive later disclosed €51 million net cash for a majority stake and up to €20 million for the remainder. M&A restarts; current results immaterial and valuation undisclosed.
• July 20, 2026 — automatic shelf registration. The S-3ASR registers a broad set of securities but contains no offering size or issuance. Routine financing optionality, not evidence of dilution.
• July 29, 2026 — Q2 beat and raise. Core growth 6.7%, adjusted EPS $0.74, FY core outlook approximately 4%, adjusted EPS $2.95–$3.05. Shares fell 7.1%. Fundamentals improved, but the market focused on gross-margin compression, AHS mix and the slower H2 bridge.
• August 10–11, 2026 — small CLO sale. Chief Legal Officer Peter Underwood sold 8,662 shares at $61.59, about $0.53 million, not flagged under a Rule 10b5-1 plan; he retained 79,118 directly owned shares. Discretionary timing but too small to drive the thesis.
• August 20, 2026 — dividend increase. Quarterly payout rose from $0.06 to $0.07. Positive signal, immaterial yield.

No material accounting-policy, critical-estimate or risk-factor change was disclosed in the Q2 filing, and no major new facility was announced through September 3. The S-3ASR does not itself issue securities. The post-July changes are therefore operating cadence, price, small M&A, capital returns and one insider sale—not a hidden reporting or corporate-structure reset.

Standing headwinds. (1) Second-half deceleration: the full-year guide implies roughly 2% H2 core growth, with Q4 losing four selling days. (2) Mix and gross margin: Q2 adjusted gross margin declined approximately 100 basis points as growth skewed toward lower-margin products and larger customers. (3) AHS conversion: recovered revenue did not produce adjusted-margin expansion. (4) Partly debt-funded repurchases: H1 cash uses exceeded FCF by approximately $312 million. (5) Low tax and acquisition accounting: the tax rate and amortization exclusions remain important props. (6) Competitive product cycles: data-center test features can be matched, software AI features are proliferating, and sterilization rivals are reinvesting. (7) Interest expense: refinancing locked in higher coupons.

Verdict. Changes since July are positive on demand, neutral-to-negative on conversion and leverage, and positive on valuation. The largest operating risk has shifted from “no volume” to “can volume persist and convert at full margin?” The largest capital-allocation risk remains a new team using debt and adjusted-EPS incentives without a formal return-on-capital hurdle.

9. Risk Analysis (Risk Matrix)

The risks cluster into one causal chain: temporary growth or adverse mix reduces operating cash; management sustains per-share optics with debt-funded repurchases or expensive M&A; tax and multiple normalize simultaneously. That combination, rather than any single product failure, defines the realistic severe downside. The company is a U.S. C-corporation, not an ADR, partnership or K-1 issuer; security-structure complexity is low. Catastrophic loss is remote, while underperformance from de-rating and capital misallocation is credible.

10. Valuation Discussion (Embedded Expectations)

Rebuilt current valuation. The AZI price series gives a September 2 close of $56.60. Multiplying by 302.017 million shares outstanding gives a $17.094 billion equity value. Adding $3.509 billion of carrying-value debt and $8.8 million of noncontrolling interests, then subtracting $374.2 million of cash, gives $20.238 billion of enterprise value. Against trailing revenue of $4.316 billion, vendor-standard EBITDA of $1.234 billion and company-defined adjusted EBITDA of $1.304 billion, that is 4.69x EV/sales, 16.4x reported EBITDA and 15.5x adjusted EBITDA. Trailing FCF of $1.044 billion is a 6.1% equity yield. The $3.00 midpoint of FY2026 adjusted-EPS guidance implies 18.9x earnings.

This reconstruction matters because vendor market caps and enterprise values can lag a share count changing rapidly through repurchases. It also distinguishes reported EBITDA from Fortive’s adjusted definition. The former is more comparable across the peer feed; the latter better matches management’s operating framework but excludes restructuring and acquisition-related items.

Live-price peer snapshot. These estimates update Q2 enterprise values for September 2 share prices while holding each company’s latest Q2 balance sheet and trailing denominator constant. They are directional, not perfectly synchronized forecasts.

Fortive sits near the middle. It is cheaper than AMETEK, IDEX and Veralto, roughly near Roper on the standardized figure, and richer than Dover, STERIS and Xylem. That spread is reasonable: Fortive has superior margin and FCF conversion to many diversified industrials but lower acquisition-inclusive ROIC and less disclosed recurrence than the best compounders. Veralto is the most revealing comparison. Its valuation is modestly higher, but its roughly high-teens ROIC and cleaner balance-sheet economics justify at least some premium.

Own-history evidence. AZI’s September 2 valuation index reports 33.4x trailing GAAP P/E, 2.83x P/B and 4.13x P/S, with percentile ranks of approximately 93rd, 73rd and 84th and a composite near the 84th percentile. These are own-history ranks, not cross-sectional cheapness. The Ralliant spin, reduced share count and amortization-heavy GAAP earnings contaminate long comparisons, so the index says “not historically cheap,” not “overvalued relative to peers.” Rebuilt forward and cash measures deserve more weight.

Embedded return requirements. At 18.9x starting adjusted earnings and an annualized dividend yield near 0.5%, achieving approximately 10% annual returns for five years requires roughly:

• 8%–9% EPS CAGR if the terminal multiple is 20x;
• about 10.5% EPS CAGR if the terminal multiple is 18x; or
• about 13% EPS CAGR if the terminal multiple is 16x.

The central route to 9%–11% EPS growth is 3%–4% organic revenue, 50–100 basis points of annual adjusted-margin expansion, and 3%–4% net share retirement. H1 shows each lever can work, but not that the recent 10% share-count decline can repeat. An alternative cash lens is less demanding: a 6.1% starting FCF yield plus 3%–4% aggregate FCF growth approximates a 9%–10% return before changes in valuation. That is the best argument that the current quote offers an adequate cushion.

Scenario framework—illustrative, not a forecast or target. In a downside case, normalized core growth returns to 1%–2%, AHS margin remains weak, tax rises and repurchases normalize; mid-single-digit EPS growth plus a 16x terminal multiple produces poor returns. In a central case, 3%–4% core growth, modest margin gains and 3% annual share shrink produce high-single-digit to low-double-digit EPS growth; an 18x terminal multiple approximately preserves a reasonable return. In an upside case, recurring/data-center/sterilization drivers sustain 4%–5% core growth while leverage stays stable; double-digit FCF growth could justify a 20x multiple. The scenarios do not require the recent $2 billion repurchase pace to continue.

Verdict. The valuation has moved from full to reasonable. At 18.9x guided adjusted EPS, 15.5x adjusted EBITDA and a 6.1% FCF yield, Fortive no longer needs a peer-premium re-rating to produce an acceptable outcome. It still needs normalized growth around 3%–4%, underlying margin expansion and disciplined capital allocation. Historical percentiles caution against calling it statistically cheap; current cash yield and peer spreads provide the margin of safety that was absent in July.

11. Variant Perception

Consensus. StockAnalysis/S&P Global, Fox Business and Barchart/Zacks snapshots cluster around $3.02 of FY2026 adjusted EPS, almost exactly the company’s midpoint. The first labels the aggregate stance Hold; the second shows 12 Holds among 18 analysts. FY2027 estimates near $3.24–$3.25 imply only about 7%–8% growth as the unusually large repurchase benefit normalizes. These secondary figures can change, but they indicate that published expectations do not underwrite another near-term earnings step-up.

Strongest bull case. H1 did more than beat estimates: it changed the composition from price-only growth to broad positive volume. TTM adjusted EBITDA margin reached 30.2%, FCF exceeded $1 billion, Fluke orders remained above sales, sterilization demand improved and software businesses introduced explicitly priced AI functionality. The current multiple is below several acknowledged compounders and the cash yield no longer requires a re-rating. If normalized core growth settles around 4% and share retirement falls to a self-fundable pace, Fortive can produce double-digit per-share growth from a much healthier mix of operating and capital levers.

Strongest bear case. H1 growth is flattered by Q1 selling days, easy comparisons and product launches; the annual guide already implies a roughly 2% second half. Q2 adjusted gross margin fell 100 basis points, AHS adjusted margin fell 80, and only one-third of GAAP operating-margin expansion came from recurring operating levers. Meanwhile, H1 capital uses exceeded FCF by $312 million, net debt funded the gap, the tax rate remained abnormally low and adjusted EPS excludes the amortization of a balance sheet that is 81% goodwill/intangibles. If organic growth reverts after Q3, the per-share compounder story remains financial engineering with only a modestly lower multiple.

The 3–5 assumptions that matter (with falsification):

1. Normalized core growth is 3%–4%, not 2%. Positive evidence: another clean 4%+ quarter with positive volume. Negative evidence: two consecutive sub-2% normalized quarters.
2. Margin gains are operational. Positive evidence: at least 50 basis points of underlying expansion after excluding amortization, restructuring and refunds. Negative evidence: two quarters of flat/down adjusted margin or continuing AHS contraction.
3. Share retirement becomes self-funded. Positive evidence: repurchases at or below FCF with stable net leverage. Negative evidence: debt keeps rising to sustain per-share growth.
4. Recurring and software claims become auditable. Positive evidence: reconciled recurring mix, ARR/NRR or AI attachment. Negative evidence: RPO and contract liabilities lag while management relies on launch anecdotes.
5. The tax rate remains within a modeled mid-teens range. A move toward 21% is not an operating failure but materially lowers per-share earnings.

Factor-positioning read (interpretation). FactorsToday gives Fortive modest negative Momentum and Growth loadings and mild Value/Small Size exposure; model fit is only moderate. Raw AZI returns were negative 6.5% over three months and negative 2.2% over six months, but positive 20.2% over twelve months. Price is below its 21-, 50- and 200-day exponential averages. The Q2 reaction was largely issuer-specific rather than a sector move, even though recent Industrials factor performance has also weakened. This is not a crowded positive-momentum setup; it is a fundamental-improvement-versus-conversion debate after expectations reset. Statistical exposures are descriptive, not causal.

Variant perception. The non-consensus insight is not simply that growth is better or valuation lower—both are visible. It is that the market may be over-penalizing the back-half cadence while still under-penalizing the cash funding mix. Selling-day arithmetic can make Q4 optically weak without undoing customer demand, so a calendar-induced slowdown should not be confused with structural relapse. Conversely, stable leverage ratios can hide borrowing when EBITDA rises; the H1 cash bridge proves repurchases were not self-funded. The best differentiated view owns both facts at once: operations are improving enough to support the valuation, but sustainable returns require buybacks to normalize before leverage does the work.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the true recurring-revenue percentage and net-revenue-retention by segment? Management claims approximately 50% recurring; the Q2 filing discloses only services at 20.1%. The gap is software, consumables, rentals and subscriptions—still unreconciled.
2. What share of Q2’s 4.3% volume is repeatable? Product launches, easier comparisons, channel restocking, share gains and end-market recovery are not separately quantified.
3. Can Q3 deliver approximately 4% core growth without calendar help, and what is Q4 on a selling-day-normalized basis? This is the cleanest near-term structural-growth test.
4. Can AHS convert recovered demand into margin? Placements, installed-base size, consumables attachment and service renewal are not disclosed.
5. Will repurchases fall to a self-funded level, or will net debt continue to fill the gap? Stable leverage ratios are insufficient if EBITDA growth masks borrowing.
6. Is a mid-teens effective tax rate sustainable under changing U.S. and OECD rules, or should the normalized model use 21%?
7. Will the restarted M&A engine show price discipline? UV Smart revenue, EBITDA, purchase multiple and accretion are undisclosed, and incentives contain no ROIC hurdle.
8. How large and durable is Fluke’s data-center opportunity? Management provides no data-center revenue, orders, share, repeat purchases or pull-through amount.
9. Does AI create revenue or merely preserve parity? Fortive discloses product launches and pricing models but no AI ARR, attachment, NRR or margin contribution.
10. Are product-level shares stable? Public primary evidence does not support precise share estimates for Fluke, ASP, Landauer, Industrial Scientific or software assets.

14. What Must Be True

For the central thesis to hold, all of the following—not merely adjusted EPS—must remain true:

1. Normalized core revenue settles at 3%–4% or better. Q3 should reach approximately 4% without selling-day help; Q4 should be judged after adding back the disclosed calendar headwind. Two consecutive normalized quarters below 2% would invalidate the growth upgrade.
2. Volume remains positive. Pricing alone cannot carry the thesis as it did in 2025. Fluke, facilities software, gas detection and sterilization need broad demand rather than one launch.
3. Underlying adjusted margin expands 50–100 basis points annually. Lower amortization, restructuring and tariff refunds do not count. AHS needs to stop diluting consolidated conversion.
4. Free cash flow remains near or above $1 billion with capex near 2%–3% of sales. Cash must continue to exceed accounting earnings without working-capital borrowing.
5. Net share retirement becomes cash-funded. A sustainable pace is likely 3%–4% annually, not the recent 10% rate. Net leverage should remain roughly 2.5x or lower without depending on EBITDA growth to hide debt-funded cash uses.
6. Tax settles in a defensible range. A mid-teens rate is plausible; the economics must still work under a 21% stress case.
7. Acquisitions earn more than the cost of capital. Future deals need disclosed prices, cash returns and post-close organic performance; strategic adjacency alone is insufficient.
8. Moat claims become measurable. Fluke share, ASP placements/consumables, gas HaaS renewals, and software ARR/NRR should stabilize or improve through a full replacement cycle.

The most important near-term observable is Q3 normalized core growth paired with the operating-margin bridge. The most important medium-term observable is the reconciliation of repurchases to FCF and net debt. Strong performance on only one axis is insufficient: better demand with poor conversion wastes the growth, while high adjusted EPS funded by borrowing does not prove compounding.

15. Public Source Appendix

Fortive Corporation (NYSE: FTV) — report date 2026-09-03. Primary sources prioritized. Facts reconciled to filings; third-party aggregated data (ROIC.ai, AZI, FactorsToday) cross-checked against primary documents and labeled.

Primary — SEC filings (EDGAR, CIK 0001659166)

Primary — company disclosures

• Q2 2026 earnings release (2026-07-29) — 6.7% core growth, segment results, FCF and raised guidance.
• Q2 2026 earnings-call transcript (call 2026-07-29) — selling-day bridge, data-center/AI claims, mix and H2 cadence; public secondary transcript cross-checked to filed figures.
• Q1 2026 earnings exhibit and call transcript (2026-04-30) — 5.3% core, roughly 150-bp calendar benefit, Fluke orders and tariff/mix cadence.
• Q4/FY2025 earnings release (2026-02-04) — adjusted-EPS bridge and initial FY2026 guide.
• Q4 2025 earnings call transcript (2026-02-04) — FY2026 framework, buyback ~600 bps EPS tailwind, AI-defensibility framing, healthcare-capital recovery.
• Q3 2025 earnings call transcript (2025-10-29) — first standalone RemainCo quarter, “Fortive Accelerator” strategy.
• Investor Day (2025-06-10) — “~50% recurring revenue” claim (management definition; unverified in 10-K), 50–100 bps/yr margin-expansion framework.
• Fortive corporate & IR site (fortive.com) — segment/brand descriptions, FBS.
• Dividend increase (2026-08-20) — $0.07 quarterly payout.

Industry & competitive (third-party)

• FDA medical-device reprocessing guidance — validation and workflow requirements; multiple clearance records confirm regulation is not exclusive.
• NRC personnel-monitoring interpretation and NIST NVLAP program — dosimetry demand floor and open accreditation hurdle.
• OSHA 29 CFR 1910.146 — vendor-neutral gas-testing requirements.
• STERIS Q1 FY2027 results, Getinge Q2 2026 and MSA Safety Q2 2026 — direct competitor demand, recurring/capital mix and supply-side investment.
• Fluke CertiFiber Max and VIAVI multifiber launch — data-center product evidence and feature contestability.
• ServiceChannel marketplace and Gordian Flash AI — provider/work-order scale and visible AI product pricing; company claims, not retention proof.

Quantitative data & cross-checks (third-party aggregated — reconciled to filings)

• ROIC.ai — standardized financial statements, ratios, enterprise value, per-share data and earnings-call transcripts. Used for trend and peer cross-checks; reconciled to filings.
• AZI valuation index — September 2 own-history percentile ranks: P/E about 93rd, P/B 73rd, P/S 84th, composite 84th; spin comparability flagged.
• AZI price CSV — five-year adjusted/unadjusted OHLCV, spin factor, EMAs and event returns through 2026-09-02.
• FactorsToday loadings, stock information and methodology — statistical exposure, price/risk cross-checks and comparable correlations.
• Comp multiples (ROIC.ai, TTM) — AME, ROP, VLTO, DOV, IEX, XYL, STE.
• StockAnalysis/S&P Global, Fox Business and Barchart/Zacks — consensus stance and FY2026/FY2027 EPS snapshots, accessed 2026-09-03; secondary and subject to change.

Notes on reliability

Management commentary (guidance, approximately 50% recurring, share gains, data-center opportunity and AI monetization) is treated as hypothesis unless a filing or external observation supports it. Filing-based calculations govern FCF, share count, debt, tax, ROIC and adjusted EBITDA; ROIC.ai provides standardized cross-checks and transcripts. All valuation percentiles are own-history, never cross-sectional. The 60-month EDGAR sweep covered five 10-Ks, 15 10-Qs, 46 8-Ks, five proxies and 435 Forms 3/4/5; every unique source-manifest path passed the local integrity check. No recommendation or price target appears outside the clearly labeled Claude’s Take block.